Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest COX-2 inhibitor Stories

2014-04-03 12:28:34

MUMBAI, India, April 3, 2014 /PRNewswire/ -- - GRC 27864 is a potent, selective, orally bioavailable inhibitor of mPGES-1 - The molecule has successfully completed pre-clinical and Phase 1 enabling studies. Regulatory submission has been filed for Phase 1 trial (first-in-human) with MHRA, UK - mPGES-1 inhibitors selectively block the production of PGE2 while sparing other prostanoids of physiological importance...

2014-03-12 20:24:16

DUBLIN, March 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib)...

2014-02-10 08:26:43

MISSISSAUGA, ON, Feb. 10, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the...

2014-01-17 08:22:56

- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 - MISSISSAUGA, ON, Jan. 17, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology today announced that the U.S. Food and Drug Administration (FDA) has approved Mallinckrodt's New Drug Application for PENNSAID(®) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a follow-on product to...

2013-10-21 08:28:17

First NSAID Developed Using SoluMatrix Fine Particle Technology(TM) PHILADELPHIA, Oct. 21, 2013 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX(TM) (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults[1]. ZORVOLEX was approved at dosage strengths...

2013-09-13 08:23:58

EUGENE, Ore., Sept. 13, 2013 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) recently announced that labeling for extended-release/long-acting (ER/LA) opioid pain relievers will no longer state that the intended use includes treatment of moderate pain. With the new restrictions on the use of these opioids, clinicians and patients will likely look to prescription and over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) as alternatives to manage moderate pain. The...

2013-08-22 08:26:44

MISSISSAUGA, ON, Aug. 22, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID(® )(diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt (NYSE:MNK) has advised that the U.S. Food and...

2013-08-20 23:04:24

Transparency Market Research published new "Pain Management Therapeutics Market (Anticonvulsants, Antidepressants, Anesthetics, NSAIDs, Opioids, Other Non-Narcotic Analgesics and Anti-Migraine Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" market research report to its report store. To browse the report, visit http://www.transparencymarketresearch.com/pain-management-therapeutics.html. Albany, New York (PRWEB) August 20, 2013...

2013-08-15 08:28:27

MISSISSAUGA, ON, Aug. 15, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensing partner for PENNSAID(® )(diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt (NYSE:MNK) has submitted the results...

2013-07-31 08:28:34

ALBANY, New York, July 31, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47...